Two companies have independently validated that RAS, a historically undruggable oncogene, can be targeted with small molecule inhibitors showing meaningful tumor shrinkage and survival benefit in pancreatic and lung cancers. Revolution Medicines' daraxonrasib demonstrated a 60%…
Three days before Erasca announced its cancer drug results Monday, the company received a letter from Revolution Medicines' lawyers alleging the drug infringes a patent. The data — 40 percent tumor shrinkage in pancreatic cancer, 62 percent in lung cancer — dropped April 27 anyway. The patent dispute did not.
That sequence is the real lede. Two companies are now racing to prove that RAS, a gene scientists spent decades calling undruggable, can be hit with pills that actually shrink tumors. Both have data supporting that case. Both are also now in a legal fight over whose intellectual property covers the target. And behind that fight is a question neither company is discussing publicly: if both drugs prove safe enough, who gets to test whether taking them together works better than either one alone?
The answer may determine which company defines the next chapter of RAS-targeted oncology — and who has to ask permission first.
Erasca's drug, ERAS-0015, posted preliminary Phase 1 results showing partial tumor responses in patients with advanced pancreatic and lung cancers. CEO Jonathan Lim called the data "compelling" on a conference call Monday, according to STAT News. The company has a market capitalization near $7 billion. The results are early — partial responses in a dose-escalation trial, not survival data — but they are consistent with what the field has been waiting to see since Revolution Medicines published its own Phase 2 results earlier this month.
Revolution Medicines' drug, daraxonrasib, cut the risk of death by 60 percent compared to chemotherapy in pancreatic cancer patients, extending median survival from 6.7 months to 13.2 months. That Phase 2 result, described by one oncologist as a potential paradigm shift for targeted therapy in front-line pancreas cancer, validated the RAS-targeting approach in a way that made combination trials thinkable for the first time. Revolution Medicines is now running a Phase 3 trial testing daraxonrasib both alone and combined with standard chemotherapy in newly diagnosed metastatic pancreatic cancer. The company's market cap has grown to somewhere between $26 billion and $30 billion.
Erasca's counter-claim is that ERAS-0015 binds to its target with 8 to 21 times greater affinity than RMC-6236, Revolution Medicines' drug, and achieves tumor regression at one-tenth to one-fifth of the dose. Those are preclinical numbers, not human data, and a Phase 1 dose-escalation trial is not where that question gets settled definitively.
What the SEC filing makes clear is that Revolution Medicines chose not to intervene publicly before the data went out, despite having the patent infringement letter in hand since April 24. Whether that reflects legal strategy, litigation caution, or something else is not answerable from the disclosure alone.
The RAS pathway has a long history in oncology. It was identified as an oncogene in the early 1980s. For decades, the gene resisted every attempt to drug it directly — earning the nickname "undruggable." The approach that finally worked — targeting the protein's interactions with helper molecules rather than the protein itself — is what both Erasca and Revolution Medicines are now exploiting. That both companies have pills that produce meaningful single-agent activity in the same cancer types is itself a significant development. The fact that they are now fighting over the intellectual property covering those pills is the field's way of confirming the prize is real.
The combination therapy question is where it gets interesting for the rest of oncology. EGFR inhibitors, the previous generation of targeted therapies, followed a predictable arc: monotherapy first, then combinations that pushed survival curves further as oncologists learned which drugs could be layered safely. RAS inhibitors are expected to follow the same path. If both ERAS-0015 and daraxonrasib ultimately prove safe enough to combine, whoever controls the relevant IP decides who runs that trial first — and at what cost. That is the prize the patent dispute is actually proxying for.
Neither company responded to requests for comment on the litigation timeline or their combination therapy plans.
What to watch: whether Revolution Medicines files a lawsuit or seeks an injunction before Erasca advances into later-stage trials, and whether either company signals openness to a licensing deal. The Phase 3 RASolute 303 trial for daraxonrasib is currently enrolling. If the patent dispute slows ERAS-0015's development path, the combination therapy future the field is quietly building toward will have one fewer participant.